Hypoxia Inducible Factor Prolyl Hydroxylase Inhibitors - Renal Disorders

Relevant Publications

Anemia of Chronic Kidney Disease-A Narrative Review of Its Pathophysiology, Diagnosis, and Management.

Issue Release: 2024

A patent review on hypoxia-inducible factor (HIF) modulators (2021-2023).

Issue Release: 2024

Evaluating the safety and efficacy of vadadustat for the treatment of anemia associated with chronic kidney disease.

Issue Release: 2024

Iron Deficiency in Newly Referred Patients With Chronic Renal Failure.

Issue Release: 2024

Activation of the hypoxia-inducible factor pathway by roxadustat improves glucose metabolism in human primary myotubes from men.

Issue Release: 2024

Efficacy of daprodustat for patients on dialysis with anemia: systematic review and network meta-analysis.

Issue Release: 2024

Endothelial PHD2 deficiency induces apoptosis resistance and inflammation via AKT activation and AIP1 loss independent of HIF2α.

Issue Release: 2024

Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors in Kidney Disease.

Issue Release: 2024

Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors as a New Treatment Option for Anemia in Chronic Kidney Disease.

Issue Release: 2024

Hypoxia-inducible factor prolyl hydroxylase inhibitors for anaemia in chronic kidney disease: a document by the European Renal Best Practice board of the European Renal Association.

Issue Release: 2024

Targeting inflammation in perivascular cells and neuroimmune interactions for treating kidney disease.

Issue Release: 2024

Roxadustat-Induced Central Hypothyroidism in Renal Anemia Patients: Insights From Antineutrophil Cytoplasmic Antibody-Related Vasculitis Cases.

Issue Release: 2024

Physician and Patient Preferences for Treatment of Anemia Associated with Chronic Kidney Disease in Japan: A Survey Including Best-Worst Scaling.

Issue Release: 2024

[Hypoxia-Inducible Factor Prolyl Hydroxylase Enzyme Inhibitors: A Novel Therapy for Anemia Treatment in CKD Patients].

Issue Release: 2024

[Update on Research and Treatment of Chronic Kidney Disease].

Issue Release: 2024

Erythrocyte indices and response to hypoxia-inducible factor prolyl hydroxylase inhibitors in chronic kidney disease patients with renal anemia: a retrospective study.

Issue Release: 2024

Successful treatment of low-risk myelodysplastic syndrome-related anemia in patients with chronic kidney disease with daprodustat: A report of two cases.

Issue Release: 2024

Growing concerns about using hypoxia-inducible factor prolyl hydroxylase inhibitors for the treatment of renal anemia.

Issue Release: 2024

Exacerbation of Diabetic Retinopathy following Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor Administration: A Case Report.

Issue Release: 2024

Kidney Fibrosis and Oxidative Stress: From Molecular Pathways to New Pharmacological Opportunities.

Issue Release: 2024

Are There Safer Alternatives?

What is Organ Rejection?

What are the Symptoms of AKI?

What is Nephrotic Syndrome?

How are ACE Inhibitors Monitored in Patients with Renal Disorders?

Why is GFR Important in Renal Disorders?

What Challenges Do Patients Face?

How Does the Transplant Procedure Work?

How Does Benazepril Affect Kidney Function?

How Does Alcohol Affect Kidney Function?

Partnered Content Networks

Relevant Topics